Abbott (ABT) Q1 2026 Earnings Call Transcript

Abbott reported Q1 adjusted EPS of $1.15, up 6% year over year, with comparable sales growth of 3.7% and reiterated confidence in a second-half growth acceleration. Management raised the full-year 2026 outlook to 6.5%-7.5% comparable sales growth, but cut the EPS midpoint to $5.48, reflecting $0.20 dilution from the Exact Sciences acquisition. Key positives included 8.5% Medical Devices growth, 13% Cancer Diagnostics growth, and $2 billion of CGM revenue, while Nutrition and Rapid/Molecular Diagnostics remained mixed.

Analysis

The core read-through is that Abbott is transitioning from a “show-me” multiple to a self-funded growth compounder, but only if the market believes the post-deal mix can reaccelerate without permanent margin leakage. The Exact Sciences integration creates a second engine in diagnostics, yet the real second-order effect is competitive: Abbott is now better positioned to cross-sell into cancer screening, payer contracts, and international channels that were previously under-monetized. That likely pressures smaller screening-adjacent competitors more than the obvious large-cap peers, because the bottleneck is not test quality alone but distribution, physician workflow integration, and reimbursement navigation.

The biggest underappreciated catalyst is not the acquisition itself but the sequencing of product launches in EP and CGM. Management is effectively telling you the 2H acceleration story is coming from multiple independent levers, which reduces idiosyncratic execution risk; if one catalyst slips, another can still carry the quarter. The flip side is that the market may be over-anchored to near-term weekly prescription noise in CGM and underestimating how much of the upside depends on reimbursement timing and international tender dynamics, both of which can move in lumpy 1-2 quarter increments.

On risk, the main trap is guidance credibility. The company is explicitly baking in conservatism on respiratory and perhaps some macro/shipping friction, which means the next disappointment would likely come from one of the “trajectory-changing” businesses failing to inflect as promised, not from the steady-state franchises. China VBP is improving but remains a latent overhang; any renewed policy wave or pricing shock would hit Core Lab psychology quickly even if reported revenue impact is delayed.

Contrarianly, the market may be too focused on whether Exact Sciences dilutes EPS by $0.20 and not enough on whether the acquisition changes Abbott’s long-duration growth rate and terminal multiple. If management can prove Cologuard rescreens, international screening pilots, and MRD/therapy-selection adjacency are real, then the asset is worth more inside Abbott than as a standalone roll-up. That makes the setup less about near-term EPS and more about whether the Street begins pricing Abbott as a diagnostics/platform winner rather than a diversified medtech with episodic growth bursts.

Key Decisions for Investors

• Long ABT on a 3-6 month horizon into the expected 2H acceleration; use pullbacks tied to CGM or respiratory noise to build. Risk/reward favors upside if the market starts capitalizing the Exact Sciences mix shift at a higher growth multiple.
• Pair trade: long ABT / short BDX or MDT over the next 1-2 quarters. Abbott has more identifiable product-led catalysts and a clearer path to re-acceleration, while peers remain more exposed to slower organic growth re-rating risk.
• Sell downside protection on ABT via puts 3-6 months out if implied vol remains elevated after the call. Management has set a conservative bar, so near-term downside appears better monetizable than upside in the options market.
• For a tactical trade, buy EXAS exposure via ABT rather than standalone EXAS for the next 6-12 months. Abbott’s distribution, balance sheet, and cross-selling can unlock value that the market may not fully attribute to the asset alone.
• Avoid shorting ABT outright; instead short the parts-of-the-market that are most exposed to screening share shift or diagnostic channel consolidation. The company’s execution cadence and diversification make a clean short low-conviction unless 2H growth inflects materially lower than guided.